InspireMD’s (NSPR) Buy Rating Reiterated at HC Wainwright
InspireMD (NYSEAMERICAN:NSPR)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Wednesday.
NSPR opened at $0.15 on Wednesday. InspireMD has a fifty-two week low of $0.13 and a fifty-two week high of $3.19.
InspireMD (NYSEAMERICAN:NSPR) last released its quarterly earnings results on Tuesday, February 19th. The medical equipment provider reported ($0.05) earnings per share for the quarter. The company had revenue of $0.82 million for the quarter.
InspireMD Company Profile
InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions.
Read More: How does new data get added to a blockchain?
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.